Elevance Health Inc.
NYSE:ELVMedical - Healthcare Plans
-$3.45 today
- Market cap
- $86.60B
- Beta
- 0.68
- P/E (TTM)
- 16.3
- EPS (TTM)
- $23.78
- Dividend yield
- 1.77%
Volume 1.91M
Average 1.68M
ELV Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Elevance Health Inc.NYSE: ELV
Financing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Financing cash flow grows, but more slowly than its trailing trend
Q3 FY2026 financing cash flow of $838M rose 244.9% year over year, behind the +418.6% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +9.7% a year.
Context
- Financing cash flow amounted to 0.9% of revenue in FY2025, up 0.2 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +244.9% toward the trailing-twelve-month pace of +418.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (1.74B) USD
- Year-over-year change
- -245.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.74B) | -245.7% |
| FY2024 | 2024-12-31 | 1.19B | +135.6% |
| FY2023 | 2023-12-31 | (3.35B) | -154.1% |
| FY2022 | 2022-12-31 | (1.32B) | -411.6% |
| FY2021 | 2021-12-31 | 423M | — |
Financing Cash Flow vs competitors
How ELV compares with its peers on the latest reported figures
- ELV's LTM Sep 2026 financing cash flow of $2.94B is the 4th largest of the 9 companies compared; the peer median is $740.81M.
- Its year-over-year change of +418.6% is the 2nd highest of 9, against a peer median of +73.1%.
- Financing cash flow amounts to 1.5% of revenue for ELV, versus a peer median of 1.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $16.06B | -15.3% | — | 3.6% | |
| LTM Jun 2026 | $8.43B | +214.0% | -22.3% | 2.0% | |
| LTM Sep 2026 | $6.44B | +15.0% | -17.0% | 2.2% | |
| LTM Sep 2026 | $2.94B | +418.6% | +9.7% | 1.5% | |
| LTM Sep 2026 | $2.08B | +162.0% | -14.1% | 1.3% | |
| LTM Jun 2026 | $1.5B | -44.1% | -27.5% | 0.8% | |
| LTM Jun 2026 | $380.76M | +671.0% | +9.9% | 2.5% | |
| LTM Sep 2026 | $61M | +131.3% | -27.2% | 0.1% | |
| LTM Mar 2026 | $18.38M | -88.3% | +2.8% | 0.4% | |
| Peer median (excluding ELV) | $740.81M | +73.1% | -17.0% | 1.7% | |
Competitors are the stored peer set for ELV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 6.1B | 6.02B | 5.99B | 5.97B | 5.66B |
| Depreciation & Amortization | 1.3B | 1.68B | 1.75B | 1.39B | 1.55B |
| Deferred Income Tax | 173M | (76M) | (602M) | (374M) | (279M) |
| Stock-Based Compensation | 255M | 264M | 289M | 191M | 276M |
| Change in Working Capital | 784M | 253M | (535M) | (1.72B) | (3.28B) |
| Accounts Receivables | (2.14B) | (2.51B) | (1.76B) | (683M) | (2.53B) |
| Inventory | 2.14B | 2.51B | 0 | 0 | 0 |
| Accounts Payables | 719M | 252M | 1.64B | (272M) | (720M) |
| Other Working Capital | 65M | 1M | (413M) | (764M) | (31M) |
| Other Non-Cash Items | (245M) | 264M | 1.18B | 346M | 363M |
| Operating Cash Flow | 8.36B | 8.4B | 8.06B | 5.81B | 4.29B |
| Capital Expenditures | (1.09B) | (1.15B) | (1.3B) | (1.26B) | (1.12B) |
| Acquisitions (Net) | (3.48B) | (649M) | (1.55B) | (4.45B) | 88M |
| Purchases of Investments | (18.67B) | (24.95B) | (16.24B) | (17.99B) | (15.03B) |
| Sales of Investments | 14.61B | 22.61B | 13.54B | 18.57B | 15.1B |
| Other Investing Activities | (1.02B) | (421M) | (24M) | (51M) | (385M) |
| Investing Cash Flow | (9.64B) | (4.56B) | (5.57B) | (5.17B) | (1.34B) |
| Debt Repayment | 2.34B | 1.8B | 739M | 5.56B | 2.33B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (1.9B) | (2.32B) | (2.68B) | (2.9B) | (2.61B) |
| Dividends Paid | (1.1B) | (1.23B) | (1.4B) | (1.51B) | (1.53B) |
| Other Financing Activities | 1.08B | 432M | (17M) | 39M | 69M |
| Financing Cash Flow | 423M | (1.32B) | (3.35B) | 1.19B | (1.74B) |
| Effect of Forex Changes | (10M) | (14M) | (1M) | (72M) | (5M) |
| Net Change in Cash | (861M) | 2.51B | (861M) | 1.76B | 1.2B |
| Free Cash Flow | 7.28B | 7.25B | 6.77B | 4.55B | 3.17B |
Elevance Health Inc.
NYSE:ELV
Intrinsic Alpha fair value
Locked
Current Price
$400.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.